Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures
Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures
Study is the first study after commercialization of brivaracetam. It is designed to collect
 real world information on the effectiveness of brivaracetam in patients with Partial Onset
 Seizure epislepsy who are treated in standard clinical practice.
EP0077 is a 12 months, multicenter, noninterventional study (NIS) conducted at specialized
 sites in approximately 10 European countries. Patients will be treated according to usual
 medical diagnostic procedures and therapy; commercially available brivaracetam will be
 prescribed according to normal clinical practice and the current Summary of Product
 Characteristics (SmPC) in Europe for brivaracetam (BRV). The prescription of BRV is clearly
 separated from the decision to include the patient in the study. No additional diagnostic or
 monitoring procedures are applied to the patients.

 The primary objective of this study is to determine BRV retention over a 12 month period as a
 measure of effectiveness in a real world setting. The secondary objective of this study is to
 assess seizure control with BRV treatment.
Inclusion Criteria:

 -  Patient has never been treated with brivaracetam (BRV) prior to enrollment in this
 Non-Interventional Study (NIS)

 -  The decision by the treating physician to prescribe BRV is made independently of the
 participation in the NIS

 -  Patient is a male or female ≥16 years of age

 -  Patient has a clinical diagnosis of epilepsy with partial-onset seizures POS with or
 without secondary generalization

 -  Patient uses an epilepsy/seizure diary.

 Exclusion Criteria:

 No specific exclusion criteria